Skip to main content

Exelixis, Inc.

corporate_fare Company Profile

Exelixis, Inc.

EXEL·NASDAQ·Life Sciences·CIK 0000939767

Exelixis, Inc. is an oncology company that develops next-generation medicines for cancer care. The company has produced four marketed pharmaceutical products. Two of these products are formulations of its primary molecule, cabozantinib. Sales from cabozantinib represent the majority of Exelixis's revenues. Cabozantinib is a tyrosine kinase inhibitor that targets MET, AXL, VEGF receptors, and RET. It is approved by the U.S. Food and Drug Administration (FDA) and in 68 other countries. As CABOMETYX® (cabozantinib) tablets, it is approved for advanced renal cell carcinoma (RCC) (both alone and in combination with Bristol-Myers Squibb Company's nivolumab (OPDIVO®)), previously treated hepatocellular carcinoma (HCC), previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET). As COMETRIQ® (cabozantinib) capsules, it is approved for progressive, metastatic medullary thyroid cancer (MTC). The other two products from Exelixis's discovery efforts are COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone). COTELLIC® (cobimetinib), a MEK inhibitor, is approved as part of multiple combination regimens to treat specific forms of advanced melanoma and is marketed in collaboration with Genentech, Inc. MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, is approved for the treatment of hypertension in Japan and is licensed to Daiichi Sankyo Company, Limited. Exelixis is also advancing its product pipeline, including zanzalintinib, which is currently under review by the FDA for certain forms of colorectal cancer (CRC) and is in late-stage clinical development for other indications.

Exelixis, Inc. (NASDAQ:EXEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for EXEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for EXEL spans SCHEDULE 13D/A, 10-Q, 8-K, DEFA14A.

Recent high-impact activity:

  • Farallon Sells ~2.6M Exelixis Shares Into Rally, Drops Below 5% Stake
  • Exelixis 10-Q: Q3 Revenue $658.7M, EPS $0.85, $1.4B Cash, Handa Generic Approved
  • Exelixis Q3 Revenue $658.7M, EPS $0.85; Tax Guidance Cut, Azurity Deal Signed
  • Exelixis Q3 Revenue Jumps 10% to $658.7M, Tax Guidance Cut, New Zanzalintinib Readout Set for Q1 2027
  • FDA Extends Zanzalintinib NDA Review by Three Months; New PDUFA Date March 3, 2027

Financial Snapshot

Fiscal year ended January 2, 2026
Revenue
$2.32B
Net Income
$782.57M
Diluted EPS
$2.78
Op. Cash Flow
$884.27M
Free Cash Flow
$875.84M
Gross Profit
$2.24B
Operating Income
$872.19M
Cash & Equivalents
$482.49M
Debt / Equity
0.00×
Net Margin
33.7%
Shares Outstanding
262.48M sh
Source: 10-K · filed 2026-02-10 · accession 0000939767-26-000021

Short Interest & Short Volume

11.71 days to cover

FINRA reported short interest of 25,593,708 shares in EXEL as of the October 30, 2026 settlement, a 6.3% decrease from the prior period — about 11.7 days to cover at its recent average daily volume. On November 20, 2026, 68.6% of EXEL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)25,593,708 shares as of October 30, 2026
Change vs prior period▼ 6.3%
Days to cover11.71 at avg daily volume of 2,185,683
Daily short volume (FINRA facilities)68.6% of 693,891 shares on November 20, 2026
5-day average short volume59.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with E →
$63.57 -1.64% today
52-week range · as of 2026-11-10 $39.71 – $73.69
Market cap
$15.77B
Volume
2.2M (0.8× avg)
3-mo avg 2.8M
Live data · 2026-11-21 11:10 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EXEL - Latest Insights

EXEL
Nov 09, 2026, 7:10 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $71.74
Real-time Price: $63.57 info
Change: -$8.17 (-11%) info
Market Cap: $15.77B info
EXEL
Oct 29, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $66.35
Real-time Price: $63.57 info
Change: -$2.78 (-4%) info
Market Cap: $15.77B info
EXEL
Oct 29, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $66.35
Real-time Price: $63.57 info
Change: -$2.78 (-4%) info
Market Cap: $15.77B info
EXEL
Oct 29, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $66.34
Real-time Price: $63.57 info
Change: -$2.77 (-4%) info
Market Cap: $15.77B info
EXEL
Sep 11, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $57.40
Real-time Price: $63.57 info
Change: +$6.17 (+11%) info
Market Cap: $15.77B info
EXEL
Aug 31, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $54.64
Real-time Price: $63.57 info
Change: +$8.93 (+16%) info
Market Cap: $15.77B info
EXEL
Aug 31, 2026, 2:31 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $54.31
Real-time Price: $63.57 info
Change: +$9.27 (+17%) info
Market Cap: $15.77B info
EXEL
Aug 05, 2026, 4:53 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $53.73
Real-time Price: $63.57 info
Change: +$9.84 (+18%) info
Market Cap: $15.77B info
EXEL
May 30, 2026, 10:03 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $50.50
Real-time Price: $63.57 info
Change: +$13.07 (+26%) info
Market Cap: $15.77B info
EXEL
May 05, 2026, 4:31 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $45.00
Real-time Price: $63.57 info
Change: +$18.57 (+41%) info
Market Cap: $15.77B info
EXEL
May 05, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $45.00
Real-time Price: $63.57 info
Change: +$18.57 (+41%) info
Market Cap: $15.77B info
EXEL
May 05, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $45.00
Real-time Price: $63.57 info
Change: +$18.57 (+41%) info
Market Cap: $15.77B info
EXEL
Apr 15, 2026, 4:20 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $44.32
Real-time Price: $63.57 info
Change: +$19.25 (+43%) info
Market Cap: $15.77B info
EXEL
Apr 15, 2026, 4:17 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $44.32
Real-time Price: $63.57 info
Change: +$19.25 (+43%) info
Market Cap: $15.77B info
EXEL
Feb 10, 2026, 4:32 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $42.75
Real-time Price: $63.57 info
Change: +$20.82 (+49%) info
Market Cap: $15.77B info
EXEL
Feb 10, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.96
Real-time Price: $63.57 info
Change: +$21.61 (+52%) info
Market Cap: $15.77B info
EXEL
Jan 12, 2026, 4:22 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $44.00
Real-time Price: $63.57 info
Change: +$19.57 (+44%) info
Market Cap: $15.77B info
EXEL
Jan 05, 2026, 6:06 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $42.40
Real-time Price: $63.57 info
Change: +$21.17 (+50%) info
Market Cap: $15.77B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets